EV Biologics, Inc. (YECO)
OTCMKTS
· Delayed Price · Currency is USD
0.143
-0.058 (-28.75%)
At close: Dec 13, 2024
EV Biologics Revenue
In the year 2017, EV Biologics had annual revenue of $9.47M, down -0.34%. EV Biologics had revenue of $2.46M in the quarter ending June 30, 2017, a decrease of -78.05%.
Revenue
9.47M
Revenue Growth
-70.48%
P/S Ratio
0.04
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.46M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
EV Biologics News
- 1 year ago - EV Biologics Updates on Funding and Sales - Accesswire
- 1 year ago - EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic - Accesswire
- 1 year ago - EV Biologics Appoints Senior Investment Banker as Corporate Finance Director - Accesswire
- 1 year ago - EV Biologics Hires Senior Chief Financial Officer - Accesswire
- 1 year ago - EV Biologics Signs Exclusive Distribution Agreement for South America - Accesswire
- 2 years ago - EV Biologics Generates Mesenchymal Stem Cell Lines - Accesswire
- 2 years ago - EV Biologics Updates on Excyte Subsidiary Funding - Accesswire
- 2 years ago - EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX - Accesswire